

# Q2 FY19 Financial results

“Through the second quarter we have delivered solid revenue growth and operating performance. In addition, we remain pleased with the integration of Bard, which is tracking in line with expectations. Looking forward to the remainder of fiscal year 2019, there are a number of drivers across our segments that will accelerate our performance in the back-half. We remain confident that our business is strong, and we will continue to deliver value to our shareholders and customers around the world.”



—Vince Forlenza, Chairman and CEO

## Q2 revenue performance



## Adjusted Q2 EPS<sup>2</sup>



## Q2 revenue performance by segment<sup>1</sup>




BD Medical

**+3.8%**



BD Interventional

**+3.5%**



BD Life Sciences

**+2.7%**

## Fiscal 2019 guidance



Revenue<sup>1</sup>

**+5.0% to +6.0%**



Adjusted EPS<sup>2</sup>

**\$11.65 to \$11.75**

<sup>1</sup> Reflects growth on a currency neutral basis, adjusted to exclude divestitures, reflects BD/Bard portfolio alignment, and an adjustment to the prior year related to customer rebates and incentive fees.

<sup>2</sup> Adjusted earnings per share growth rate is presented on a currency neutral basis. Adjusted diluted earnings per share results exclude, among other things, the impact of purchase accounting adjustments (including the non-cash amortization of acquisition-related intangible assets); integration, and restructuring and transaction costs.

These materials also include non-GAAP financial measures. A reconciliation to the comparable GAAP measures can be found in our earnings release and the financial schedules attached thereto. A copy of our earnings release, including the financial schedules, is posted on the “Investors” section of the BD.com website. This document contains forward-looking statements and it’s possible that actual results could differ from our expectations. Factors that could cause such differences appear in our earnings release furnished as an exhibit to the Form 8-K that BD filed today with the SEC, and in our recent SEC filings.

